According to the FDA-approved product label, gabapentin is used clinically in the management of postherpetic neuralgia in adults and as an adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization in adults and pediatric patients 3 years and older with epilepsy.
Between 2011 and 2021, the annual total prescriptions dispensed for gabapentin steadily increased, roughly two-fold. According to IQVIA National Prescription Audit™, total prescriptions dispensed for gabapentin were approximately 33.4 million in 2011, 56.9 million in 2015, 68.3 million in 2019, 69.0 million in 2020, and 70.9 million in 2021.
Gabapentin is available in various dosage forms and strengths including capsule strengths of 100, 300 and 400 milligrams, tablet strengths of 600 and 800 milligrams and the oral liquid form is typically produced as a 250 milligrams/5 mL solution.